Ipsen S.A. (IPSEF)
- Previous Close
0.00 - Open
132.50 - Bid 101.20 x 42300
- Ask 124.25 x 40000
- Day's Range
132.50 - 132.50 - 52 Week Range
103.50 - 132.50 - Volume
2,416 - Avg. Volume
34 - Market Cap (intraday)
9.776B - Beta (5Y Monthly) 0.21
- PE Ratio (TTM)
21.43 - EPS (TTM)
4.83 - Earnings Date Jul 31, 2025
- Forward Dividend & Yield 1.45 (1.41%)
- Ex-Dividend Date Jun 4, 2025
- 1y Target Est
--
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
www.ipsen.com5,358
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: IPSEF
View More
Performance Overview: IPSEF
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IPSEF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IPSEF
View MoreValuation Measures
Market Cap
9.74B
Enterprise Value
9.45B
Trailing P/E
21.41
Forward P/E
9.03
PEG Ratio (5yr expected)
0.65
Price/Sales (ttm)
2.13
Price/Book (mrq)
1.81
Enterprise Value/Revenue
2.34
Enterprise Value/EBITDA
7.09
Financial Highlights
Profitability and Income Statement
Profit Margin
9.68%
Return on Assets (ttm)
8.23%
Return on Equity (ttm)
8.93%
Revenue (ttm)
3.57B
Net Income Avi to Common (ttm)
355.9M
Diluted EPS (ttm)
4.83
Balance Sheet and Cash Flow
Total Cash (mrq)
679.2M
Total Debt/Equity (mrq)
12.33%
Levered Free Cash Flow (ttm)
72.58M